SUBSEQUENT EVENTS	3 Months Ended
Jan. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTOn March 1, 2021 we signed an agreement to acquire privately-owned Resolution Bioscience, Inc., a biotechnology company focused on the development of next generation sequencing liquid biopsy cancer diagnostics, for $550 million cash plus potential future contingent payments of up to $145 million upon the achievement of certain milestones. The acquisition is expected to close in the second quarter of fiscal year 2021, subject to regulatory approval and customary closing conditions. The financial results of the business will be included in our financial results from the day of close.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration